A drug safety review of treating eosinophilic asthma with monoclonal antibodies

References

• Assaf SM, Hanania NA. Biological treatments for severe asthma. Curr Opin Allergy Clin Immunol. 2019;19(4):379–386.
   PubMed Web of Science ®Google Scholar
• Kelly BT, Grayson MH. Immunoglobulin E, what is it good for? Ann Allergy Asthma Immunol. 2016;116(3):183–187.
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184–190.
   PubMed Web of Science ®Google Scholar
• Holgate S, Bousquet J, Wenzel S, et al. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin. 2001;17(4):233–240.
   PubMed Web of Science ®Google Scholar
• Busse WW, Lemanske RF Jr. Asthma. N Engl J Med. 2001;344(5):350–362.
   PubMed Web of Science ®Google Scholar
• Salvi SS, Babu KS. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med. 2000;342(17):1292–1293.
   PubMed Web of Science ®Google Scholar
• Milgrom H, Fick RB Jr., Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 study group. N Engl J Med. 1999;341(26):1966–1973.
   PubMed Web of Science ®Google Scholar
• Easthope S, Jarvis B. Omalizumab. Drugs. 2001;61(2):253–260. discussion 261.
   PubMed Web of Science ®Google Scholar
• Kishimoto I, Kambe N, Ly NTM, et al. Basophil count is a sensitive marker for clinical progression in a chronic spontaneous urticaria patient treated with omalizumab. Allergol Int. 2019.
   Web of Science ®Google Scholar
• Deza G, Bertolin-Colilla M, Sanchez S, et al. Basophil FcvarepsilonRI expression is linked to time to omalizumab response in chronic spontaneous urticaria. J Allergy Clin Immunol. 2018;141(6):2313–2316.e1.
   PubMed Web of Science ®Google Scholar
• Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med. 2006;354(25):2689–2695.
   PubMed Web of Science ®Google Scholar
• Tharp MD, Bernstein JA, Kavati A, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of “real-world” evidence. JAMA Dermatol. 2018.
   Web of Science ®Google Scholar
• Adachi M, Kozawa M, Yoshisue H, et al. Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan. Respir Med. 2018;141:56–63.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011;139(1):28–35.
   PubMed Web of Science ®Google Scholar
• Djukanovic R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170(6):583–593.
   PubMed Web of Science ®Google Scholar
• Khan DA. Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist. Ann Allergy Asthma Immunol. 2016;117(2):115–120.
   PubMed Web of Science ®Google Scholar
• Lai T, Wang S, Xu Z, et al. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Sci Rep. 2015;5:8191.
   PubMed Web of Science ®Google Scholar
• Di Bona D, Fiorino I, Taurino M, et al. Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study. Respir Med. 2017;130:55–60.
   PubMed Web of Science ®Google Scholar
• Baker DL, Nakamura GR, Lowman HB, et al. Evaluation of IgE antibodies to omalizumab (Xolair(R)) and their potential correlation to anaphylaxis. Aaps J. 2016;18(1):115–123.
   PubMed Web of Science ®Google Scholar
• Lieberman PL, Umetsu DT, Carrigan GJ, et al. Anaphylactic reactions associated with omalizumab administration: analysis of a case-control study. J Allergy Clin Immunol. 2016;138(3):913–915.e2.
   PubMed Web of Science ®Google Scholar
• Apter AJ, Kinman JL, Bilker WB, et al. Represcription of penicillin after allergic-like events. J Allergy Clin Immunol. 2004;113(4):764–770.
   PubMed Web of Science ®Google Scholar
• Kawakami T, Blank U. From IgE to Omalizumab. J Immunol. 2016;197(11):4187–4192.
   PubMed Web of Science ®Google Scholar
• Matin N, Tabatabaie O, Falsaperla R, et al. Efficacy and safety of omalizumab in paediatric age: an update of literature data. J Biol Regul Homeost Agents. 2016;30(2):579–584.
   PubMed Web of Science ®Google Scholar
• Cooper PJ, Ayre G, Martin C, et al. Geohelminth infections: a review of the role of IgE and assessment of potential risks of anti-IgE treatment. Allergy. 2008;63(4):409–417.
   PubMed Web of Science ®Google Scholar
• Esquivel A, Busse WW, Calatroni A, et al. Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma. Am J Respir Crit Care Med. 2017;196(8):985–992.
   PubMed Web of Science ®Google Scholar
• Ali AK, Hartzema AG. Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting. J Asthma Allergy. 2012;5:1–9.
   PubMedGoogle Scholar
• Iribarren C, Rahmaoui A, Long AA, et al. Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study in moderate to severe asthma. J Allergy Clin Immunol. 2017;139(5):1489–1495.e5.
   PubMed Web of Science ®Google Scholar
• Iribarren C, Rothman KJ, Bradley MS, et al. Cardiovascular and cerebrovascular events among patients receiving omalizumab: pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials. J Allergy Clin Immunol. 2017;139(5):1678–1680.
   PubMed Web of Science ®Google Scholar
• Long A, Rahmaoui A, Rothman KJ, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014;134(3):560–567.e4.
   PubMed Web of Science ®Google Scholar
• Busse W, Buhl R, Fernandez Vidaurre C, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol. 2012;129(4):983–9.e6.
   PubMed Web of Science ®Google Scholar
• Namazy J, Cabana MD, Scheuerle AE, et al. The Xolair pregnancy registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol. 2015;135(2):407–412.
   PubMed Web of Science ®Google Scholar
• Schatz M, Krishnan JA, Chambers C. Implications of changes in U.S. food and drug administration prescribing information regarding the safety and use of asthma biologics during pregnancy. Ann Am Thorac Soc. 2018;15(10):1131–1136.
   PubMed Web of Science ®Google Scholar
• Ensina LF, Cusato-Ensina AP, Camelo-Nunes IC, et al. Omalizumab as third-line therapy for urticaria during pregnancy. J Investig Allergol Clin Immunol. 2017;27(5):326–327.
   PubMed Web of Science ®Google Scholar
• Cuervo-Pardo L, Barcena-Blanch M, Radojicic C. Omalizumab use during pregnancy for CIU: a tertiary care experience. Eur Ann Allergy Clin Immunol. 2016;48(4):145–146.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Simpson EL, Tyring SK, et al. Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2019;80(1):158–167.e1.
   PubMed Web of Science ®Google Scholar
• Sastre J, Davila I. Dupilumab: a new paradigm for the treatment of allergic diseases. J Investig Allergol Clin Immunol. 2018;28(3):139–150.
   PubMed Web of Science ®Google Scholar
• Walsh GM. Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma. Expert Rev Respir Med. 2018;12(11):957–963.
   PubMed Web of Science ®Google Scholar
• Dupilumab. Drugs and lactation database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006.
   Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485.
   PubMed Web of Science ®Google Scholar
• Menzella F, Montanari G, Patricelli G, et al. A case of chronic eosinophilic pneumonia in a patient treated with dupilumab. Ther Clin Risk Manag. 2019;15:869–875.
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496.
   PubMed Web of Science ®Google Scholar
• Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019.
   Web of Science ®Google Scholar
• Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–2466.
   PubMed Web of Science ®Google Scholar
• Tofte SJ, Papp K, Sadick N, et al. Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials. J Am Assoc Nurse Pract. 2018;30(9):529–541.
   PubMed Web of Science ®Google Scholar
• Zayed Y, Kheiri B, Banifadel M, et al. Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials. J Asthma. 2018;1–10.
   PubMed Web of Science ®Google Scholar
• Gleich GJ, Klion AD, Lee JJ, et al. The consequences of not having eosinophils. Allergy. 2013;68(7):829–835.
   PubMed Web of Science ®Google Scholar
• Bagnasco D, Caminati M, Ferrando M, et al. Anti-IL-5 and IL-5Ra: efficacy and safety of new therapeutic strategies in severe uncontrolled asthma. Biomed Res Int. 2018;2018:5698212.
   PubMed Web of Science ®Google Scholar
• Hart TK, Cook RM, Zia-Amirhosseini P, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol. 2001;108(2):250–257.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659.
   PubMed Web of Science ®Google Scholar
• Shimoda T, Odajima H, Okamasa A, et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergol Int. 2017;66(3):445–451.
   PubMed Web of Science ®Google Scholar
• Lugogo N, Domingo C, Chanez P, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther. 2016;38(9):2058–2070.e1.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197.
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400.
   PubMed Web of Science ®Google Scholar
• Leung E, Al Efraij K, FitzGerald JM. The safety of mepolizumab for the treatment of asthma. Expert Opin Drug Saf. 2017;16(3):397–404.
   PubMed Web of Science ®Google Scholar
• Roufosse FE, Kahn JE, Gleich GJ, et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol. 2013;131(2):461–467.
   PubMed Web of Science ®Google Scholar
• Robinson DS. Mepolizumab treatment for asthma. Expert Opin Biol Ther. 2013;13(2):295–302.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989–995.
   PubMed Web of Science ®Google Scholar
• Antoniu SA. Mepolizumab for difficult-to-control asthma with persistent sputum eosinophilia. Expert Opin Investig Drugs. 2009;18(6):869–871.
   PubMed Web of Science ®Google Scholar
• Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360(10):985–993.
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–984.
   PubMed Web of Science ®Google Scholar
• Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2018.
   PubMed Web of Science ®Google Scholar
• Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176(11):1062–1071.
   PubMed Web of Science ®Google Scholar
• Kasuya A, Kitano S, Hoshino T, et al. Successful control of severe eosinophilic granulomatosis with polyangiitis in a pregnancy and perinatal period: A use of mepolizumab. J Dermatol. 2019.
   Web of Science ®Google Scholar
• Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358(12):1215–1228.
   PubMed Web of Science ®Google Scholar
• Kim S, Marigowda G, Oren E, et al. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125(6):1336–1343.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Mariette X, Silva JT, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018;24(Suppl 2):S21–s40.
   PubMed Web of Science ®Google Scholar
• Cooper K, Frampton G, Harris P, et al. Reslizumab for treating asthma with elevated blood eosinophils inadequately controlled by inhaled corticosteroids: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2018;36(5):545–553.
   PubMed Web of Science ®Google Scholar
• Murphy K, Jacobs J, Bjermer L, et al. Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma. J Allergy Clin Immunol Pract. 2017;5(6):1572–1581.e3.
   PubMed Web of Science ®Google Scholar
• Li J, Wang F, Lin C, et al. The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: A systematic review and meta-analysis. J Asthma. 2017;54(3):300–307.
   PubMed Web of Science ®Google Scholar
• Markham A. Reslizumab: first global approval. Drugs. 2016;76(8):907–911.
   PubMed Web of Science ®Google Scholar
• Reslizumab (Cinqair) for severe eosinophilic asthma. Med Lett Drugs Ther. 2016;58(1497):81–82.
   PubMed Web of Science ®Google Scholar
• Pelaia G, Vatrella A, Busceti MT, et al. Role of biologics in severe eosinophilic asthma - focus on reslizumab. Ther Clin Risk Manag. 2016;12:1075–1082.
   PubMed Web of Science ®Google Scholar
• Paton DM. Reslizumab: maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids. Drugs Today (Barc). 2016;52(6):323–329.
   PubMed Web of Science ®Google Scholar
• Lim HF, Nair P. Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma. Expert Rev Respir Med. 2015;9(2):135–142.
   PubMed Web of Science ®Google Scholar
• Maspero J. Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects. Ther Adv Respir Dis. 2017;11(8):311–325.
   PubMed Web of Science ®Google Scholar
• Brusselle G, Germinaro M, Weiss S, et al. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulm Pharmacol Ther. 2017;43:39–45.
   PubMed Web of Science ®Google Scholar
• Hom S, Pisano M. Reslizumab (Cinqair): an Interleukin-5 antagonist for severe asthma of the eosinophilic phenotype. P&T. 2017;42(9):564–568.
   PubMedGoogle Scholar
• Corren J, Weinstein S, Janka L, et al. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150(4):799–810.
   PubMed Web of Science ®Google Scholar
• guidelines, N.B., 2019.
   Google Scholar
• Goldman M, Hirsch I, Zangrilli JG, et al. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies. Curr Med Res Opin. 2017;33(9):1605–1613.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141.
   PubMed Web of Science ®Google Scholar
• Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879–890.
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–2458.
   PubMed Web of Science ®Google Scholar
• Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7(1):46–59.
   PubMed Web of Science ®Google Scholar
• Brightling CE, Chanez P, Leigh R, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015;3(9):692–701.
   PubMed Web of Science ®Google Scholar
• Naik SP, Mahesh PA, Jayaraj BS, et al. Evaluation of inflammatory markers interleukin-6 (IL-6) and matrix metalloproteinase-9 (MMP-9) in asthma. J Asthma. 2017;54(6):584–593.
   PubMed Web of Science ®Google Scholar